PMID- 29098166
OWN - NLM
STAT- MEDLINE
DCOM- 20180709
LR  - 20190723
IS  - 2314-6753 (Electronic)
IS  - 2314-6745 (Print)
VI  - 2017
DP  - 2017
TI  - Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A 
      Review in Type 2 Diabetes.
PG  - 5164292
LID - 10.1155/2017/5164292 [doi]
LID - 5164292
AB  - Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal 
      disease (ESRD) worldwide and one of the main causes of death in diabetic 
      patients. It is also acknowledged as an independent risk factor for 
      cardiovascular disease (CVD). Since sitagliptin was approved, many studies have 
      been carried out revealing its ability to not only improve metabolic control but 
      also ameliorate dysfunction in various diabetes-targeted organs, especially the 
      kidney, due to putative underlying cytoprotective properties, namely, its 
      antiapoptotic, antioxidant, anti-inflammatory, and antifibrotic properties. 
      Despite overall recommendations, many patients spend a long time well outside the 
      recommended glycaemic range and, therefore, have an increased risk for developing 
      micro- and macrovascular complications. Currently, it is becoming clearer that 
      type 2 diabetes mellitus (T2DM) management must envision not only the improvement 
      in glycaemic control but also, and particularly, the prevention of pancreatic 
      deterioration and the evolution of complications, such as DN. This review aims to 
      provide an overview of the current knowledge in the field of renoprotective 
      actions of sitagliptin, namely, improvement in diabetic dysmetabolism, 
      hemodynamic factors, renal function, diabetic kidney lesions, and cytoprotective 
      properties.
FAU - Mega, Cristina
AU  - Mega C
AUID- ORCID: 0000-0002-9913-875X
AD  - Agrarian School of Viseu (ESAV), Polytechnic Institute of Viseu (IPV), 3500-606 
      Viseu, Portugal.
AD  - Centre for the Study of Education, Technologies and Health (CI&DETS), Polytechnic 
      Institute of Viseu (IPV), 3500-606 Viseu, Portugal.
AD  - Institute of Pharmacology and Experimental Therapeutics and Institute for 
      Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of 
      Coimbra, 3000-548 Coimbra, Portugal.
FAU - Teixeira-de-Lemos, Edite
AU  - Teixeira-de-Lemos E
AUID- ORCID: 0000-0002-6346-8319
AD  - Agrarian School of Viseu (ESAV), Polytechnic Institute of Viseu (IPV), 3500-606 
      Viseu, Portugal.
AD  - Centre for the Study of Education, Technologies and Health (CI&DETS), Polytechnic 
      Institute of Viseu (IPV), 3500-606 Viseu, Portugal.
FAU - Fernandes, Rosa
AU  - Fernandes R
AUID- ORCID: 0000-0001-7828-2296
AD  - Institute of Pharmacology and Experimental Therapeutics and Institute for 
      Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of 
      Coimbra, 3000-548 Coimbra, Portugal.
AD  - CNC.IBILI Research Consortium, University of Coimbra, 3004-504 Coimbra, Portugal.
FAU - Reis, Flavio
AU  - Reis F
AUID- ORCID: 0000-0003-3401-9554
AD  - Institute of Pharmacology and Experimental Therapeutics and Institute for 
      Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of 
      Coimbra, 3000-548 Coimbra, Portugal.
AD  - CNC.IBILI Research Consortium, University of Coimbra, 3004-504 Coimbra, Portugal.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170827
PL  - England
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Protective Agents)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Diabetic Nephropathies/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Humans
MH  - Protective Agents/*therapeutic use
MH  - Sitagliptin Phosphate/*therapeutic use
MH  - Treatment Outcome
PMC - PMC5643039
EDAT- 2017/11/04 06:00
MHDA- 2018/07/10 06:00
PMCR- 2017/08/27
CRDT- 2017/11/04 06:00
PHST- 2017/05/21 00:00 [received]
PHST- 2017/07/12 00:00 [accepted]
PHST- 2017/11/04 06:00 [entrez]
PHST- 2017/11/04 06:00 [pubmed]
PHST- 2018/07/10 06:00 [medline]
PHST- 2017/08/27 00:00 [pmc-release]
AID - 10.1155/2017/5164292 [doi]
PST - ppublish
SO  - J Diabetes Res. 2017;2017:5164292. doi: 10.1155/2017/5164292. Epub 2017 Aug 27.